BioStem Technologies Files S-1 Registration for U.S. IPO
BioStem Technologies, Inc. filed an S-1 registration statement with the U.S. Securities and Exchange Commission on October 2, 2026, initiating its IPO process on NASDAQ or NYSE. The filing does not disclose target offering size or underwriters, but marks entry into the critical SEC registration phase.
51CFO view：S-1 filing triggers immediate SOX 404(a) readiness assessment. CFO must demonstrate direct SEC registration experience, GAAP financial statement preparation under PCAOB audit standards, and ability to lead cross-border audit coordination — requiring a US-qualified controller and SEC disclosure counsel.
BioStem Technologies, Inc. filed an S-1 registration statement with the U.S. Securities and Exchange Commission on October 2, 2026, initiating its IPO process on NASDAQ or NYSE. The filing does not disclose target offering size or underwriters, but marks entry into the critical SEC registration phase.
Source：SEC EDGAR · S-1 招股书备案